Back to News
Panoramic Covid-19 Antiviral Trial
Posted on 7 Apr 2022
The Panoramic trial will offer antiviral treatments for eligible patients with confirmed COVID-19 in the UK. Trialparticipants will receive oral treatment at home, delivered directly from a central pharmacy comissioned as part of the clinical trial.
Who is eligible to take part in the trial?
Panoramic will prioritise those at greater risk of being severly ill if they test positive for COVID-19.
To be eligible, patients must:
- be unwell with symptoms of COVID-19 that started in the last 5 days
- have received a positive PCR test for COVID-19
- be aged 50 years and above OR 18-49 years old with an underlying medical condition that can increase chance of having severe COVID-19
- live anywhere across all four UK nations
The health conditions that make people eligible for the national study include:
- chronic respiratory disease including COPD, cystic fibrosis, and asthma requiring at least daily use of preventative/reliever medication.
- chronic heart or vascular disease
- chronic kidney disease
- chronic liver disease
- chronic neurological disease (inc dementia, stroke, epilepsy)
- severe and profound learning disability
- Down's syndrome
- Diabetes mellitus
- Immunosuppression: primary (inherited immune disorders resulting from genetic mutations, usually present at birth and diagnosed in childhood) or secondary due to disease or treatment (sickle cell, HIV, cancer, chemotherapy)
- solid organ, bone marrow, or stem cell transplant recipients
- morbid Obesity (BMI>35)
- severe mental illness
- care home resident
- considered by recruiting Clinician to be clinically vunerable.
How can patients take part in Panoramic?
Patients who meet the criteria can sign up themselves through this link:
Informed, consented patients will be randomised to one of two arms:
- usual care or
- usual care and to be in receipt of a new antiviral treatment to take twice daily for 5 days.
All participants will be required to complete a daily diary for 28 days through the PANORAMIC website or receive a phone call on days 7, 14 and 28 to speak about their symptoms. This data will help the NHS to develop plans on how to best make Molnupiravir available in the future to patients who would benefit most from this treatment.